By Peter Loftus
Novo Nordisk's American depositary receipts tumbled almost 6% Friday after the drugmaker reported mixed results from a study of an experimental weight-loss pill.
The pill, monlunabant, helped people lose weight in the mid-stage study, but Leerink Partners called the magnitude "underwhelming," and analysts noted that some patients had anxiety and other neuropsychiatric side effects.
Novo, which makes a leading injected anti-obesity drug Wegovy, will continue to test the experimental pill with hopes of bringing it to market.
Its stock-price decline underscores just how closely investors are following the industry race to develop a weight-loss pill that may be less expensive and easier to manufacture than injected drugs like Wegovy and Eli Lilly's Zepbound.
Conversely, shares of rival weight-loss pill developers Eli Lilly, Structure Therapeutics and Viking Therapeutics all rose Friday.
Lilly, Novo and Sanofi came into the crosshairs of regulators Friday when the U.S. Federal Trade Commission warned that it might sue them over their roles in rising insulin prices. The FTC said Friday it had sued pharmacy-benefit managers, accusing them of profiting from high insulin prices.
This item is part of a Wall Street Journal live coverage event. The full stream can be found by searching P/WSJL (WSJ Live Coverage).
(END) Dow Jones Newswires
September 20, 2024 13:17 ET (17:17 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。